<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MIL</title>
	<atom:link href="http://www.stockbloghub.com/tag/mil/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MIL) Millipore Quarterly Earnings Report Ahead of Expectations</title>
		<link>http://www.stockbloghub.com/2010/05/07/mil-millipore-quarterly-earnings-report-ahead-of-expectations/36525</link>
		<comments>http://www.stockbloghub.com/2010/05/07/mil-millipore-quarterly-earnings-report-ahead-of-expectations/36525#comments</comments>
		<pubDate>Fri, 07 May 2010 16:28:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36525</guid>
		<description><![CDATA[Millipore Corp. (MIL) reported first-quarter earnings per share of $1.21, well above the Zacks Consensus Estimate of $1.09 and the year-ago earnings of $1.06. Revenues for the first quarter grew 14% to $463 million. Excluding a 5% benefit from changes in foreign currency, Millipore generated organic revenue growth of 9%. While the Bioprocess division recorded a growth of 12% with sales coming in at $258.3 million, the Bioscience division grew 15% to $204.7 million. New product sales and increased demand from biotech customers helped the Bioprocess division generate organic growth of 13% during the quarter. A major part of the growth was driven by biotech customers in North America and Asia. Demand should remain strong with large pharma companies increasing their investment in biotech drugs. We believe Millipore will gain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/07/mil-millipore-quarterly-earnings-report-ahead-of-expectations/36525/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MIL) Merck KGaA Buys Millipore (Revised)</title>
		<link>http://www.stockbloghub.com/2010/03/03/mil-merck-kgaa-buys-millipore-revised/29494</link>
		<comments>http://www.stockbloghub.com/2010/03/03/mil-merck-kgaa-buys-millipore-revised/29494#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:35:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29494</guid>
		<description><![CDATA[Millipore Corporation (MIL), a leading life science company, and Merck KGaA, the Germany-based pharmaceutical and chemicals company, entered into a definitive agreement under which Merck will acquire all outstanding shares of common stock of Millipore for US$107 per share in cash, or a total transaction value Incorporatedluding net debt, of approximately €5.3 billion (US$7.2 billion). MercK KGaA, also called the German Merck or Merck Dermstadt is one of the oldest chemical and pharmaceutical companies in the world. The company lost its foreign assets following the First World War Incorporatedluding its U.S. subsidiary that eventually became Merck &#38; Company (MRK). Since Merck &#38; Company holds the rights to the Merck name in the U.S., Merck KGaA operates here under the name EMD Chemicals (EMD stands for Emanuel Merck, Dermstadt). Merck KGaA ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/mil-merck-kgaa-buys-millipore-revised/29494/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MIL) Millipore Corporation&#8217;s Earnings Report Tops Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/03/mil-millipore-corporations-earnings-report-tops-estimates/26916</link>
		<comments>http://www.stockbloghub.com/2010/02/03/mil-millipore-corporations-earnings-report-tops-estimates/26916#comments</comments>
		<pubDate>Wed, 03 Feb 2010 20:23:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26916</guid>
		<description><![CDATA[Millipore Corp. (MIL) reported fourth-quarter earnings per share of $1.00, seven cents above the Zacks Consensus Estimate of $0.93. Fourth quarter earnings increased 5.2% from the year-ago period. Earnings for the full year 2009 came in at $4.00, beating the Zacks Consensus Estimate of $3.94 and the year-ago earnings of $3.59. Revenues for the fourth quarter grew 7% to $426 million. Excluding a 5% benefit from changes in foreign currency, Millipore generated organic revenue growth of 2%. While the Bioprocess division recorded growth of 9% with sales coming in at $232 million, the Bioscience division grew 6% to $194 million. For the full year, revenues increased 3% to $1.6 billion with the Bioprocess and Bioscience divisions contributing $925.8 million (up 5%) and $728.6 million (up 1%), respectively. New product sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/03/mil-millipore-corporations-earnings-report-tops-estimates/26916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MIL) Millipore Corporation Buys Remaining Stake in India</title>
		<link>http://www.stockbloghub.com/2009/11/25/mil-millipore-corporation-buys-remaining-stake-in-india/21241</link>
		<comments>http://www.stockbloghub.com/2009/11/25/mil-millipore-corporation-buys-remaining-stake-in-india/21241#comments</comments>
		<pubDate>Wed, 25 Nov 2009 19:10:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21241</guid>
		<description><![CDATA[Millipore Corp. (MIL) yesterday announced the acquisition of the remaining 60% ownership of its joint-venture in India, Millipore India Pvt. Ltd. The new subsidiary will enable Millipore to invest in initiatives that will drive growth and expand its leadership in India’s thriving life science market. According to the management, over the years India has experienced unprecedented levels of investment and expansion in its biotechnology, pharmaceutical, and life science research industries. The Indian government has invested $1.7 billion to grow the country’s life science and biotechnology industries and several Indian companies have emerged as global competitors in the biopharmaceutical industry. Thus, establishing direct operations in the country will help Millipore execute its strategy more efficiently. It will also facilitate the company leverage its unique capabilities to accelerate growth and support the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/mil-millipore-corporation-buys-remaining-stake-in-india/21241/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MIL) Millipore Corporation Falls Short of Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/08/mil-millipore-corporation-falls-short-of-estimates/19894</link>
		<comments>http://www.stockbloghub.com/2009/11/08/mil-millipore-corporation-falls-short-of-estimates/19894#comments</comments>
		<pubDate>Sun, 08 Nov 2009 23:38:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[Pall Corporation]]></category>
		<category><![CDATA[PLL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19894</guid>
		<description><![CDATA[Millipore Corp. (MIL) reported third-quarter earnings per share of 71 cents, well below the Zacks Consensus Estimate of 93 cents per share. Revenues for the third quarter grew 4% from the previous year, totaling $412 million. Excluding a 3% unfavorable impact from changes in foreign currency, Millipore generated organic revenue growth of 7%. On a divisional basis, excluding changes in foreign currency, Millipore’s Bioprocess Division generated organic revenue growth of  8%, while the company’s Bioscience Division generated organic revenue growth of 4% from the previous year. In the Americas, revenue grew by 4% year over year while Asia recorded a 16% growth in revenues when compared to a similar period. Bioprocess Division is sustaining its strong momentum and generating very attractive growth. The division’s performance has returned to tracking the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/mil-millipore-corporation-falls-short-of-estimates/19894/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

